Compositions comprising bacterial strains
Provided are compositions comprising a bacterial strain of the genus Blautia , for use in a method of increasing the microbiota diversity and/or stability of the microbiota of a subject.
1. A method of inducing a temporal variation as determined by fecal sample analysis in the gastrointestinal flora microbiota of a subject having autism in need thereof, comprising administering to the subject a composition that comprises a therapeutically effective amount of a bacteria strain of Blautia hydrogenotrophica with at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:5, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62, wherein the administering is effective to induce the temporal variation in the microbiota of the subject having the autism.
2. The method of claim 1 , wherein the subject has the autism and the administering induces a temporal increase of a bacteria from the genus Clostridium XIVa, of the species Bacteroides acidifaciens , of the species Alistipes finegoldii , from the genus Barnesiella , from the family Porphyromonadaceae, from the genus Alistipes , of the species Alistipes massiliensis , from the family Lachnospiraceae, from the family Erysipelotrichaceae, from the genus Clostridium IV, or of the species Clostridium lactatifermentans , or a temporal decrease of a bacteria of the species Eubacterium ventriosum , of the species Akkermansia muciniphila , or from the genus Blautia XIVa.
3. The method of claim 1 , wherein the bacteria strain is dried.
4. The method of claim 1 , wherein the therapeutically effective amount of the bacteria strain comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU)/g of the bacteria strain with respect to the total weight of the composition.
5. The method of claim 1 , wherein the therapeutically effective amount of the bacteria strain comprises at least 1×10 6 CFU/g of the bacteria strain with respect to the total weight of the composition.
6. The method of claim 1 , wherein the bacteria strain comprises a polynucleotide sequence of a 16S rRNA gene that has at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO:5, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62.
7. The method of claim 1 , wherein the bacteria strain comprises the polynucleotide sequence of SEQ ID NO:5.
8. The method of claim 1 , wherein said administering comprises oral, rectal, nasal, buccal, sublingual, or subcutaneous administration.
9. The method of claim 1 , wherein the composition is formulated for delivery to an intestine of the subject.
10. The method of claim 1 , wherein the composition is encapsulated.
11. The method of claim 1 , wherein the composition comprises an enteric coating.
12. The method of claim 1 , further comprising administering an additional therapeutic agent to the subject.
13. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient, diluent, or carrier.
14. The method of claim 1 , wherein the subject is human.